About Us-康思葆

 ... About Us ... About CansBio

About CansBio

With 20 years of in-depth expertise in biological cell technology

We have built three major life defense lines and precisely intervene in the disease process with cell and gene technologies: preventing diseases and fighting cancer to extend the length of life; achieving scientific anti-aging to awaken youthful vitality; and managing chronic diseases to reshape a quality life. Every technological breakthrough stems from the awe for life, and every innovation carries the commitment to family health.

In the future, Cansbio will continue to refine its technologies with the spirit of craftsmanship and convey care with the benevolence of medical workers, becoming your trustworthy "lifelong health partner".

Company Profile

CansBio (Beijing) Biotechnology Co., Ltd., founded in 2007 and headquartered in Beijing Economic and Technological Development Zone, is a high-tech enterprise dedicated to scientific research and achievement transformation in the field of cell and gene technologies. With "technology-driven life health management" as its core, the company focuses on tumor immunotherapy, anti-aging and regenerative medicine, and is committed to providing professional support for health management through cutting-edge biological technologies and redefining precision medicine with cell and gene technologies.

Since introducing the NK cell technology from Odaka Hospital (Japan) in 2007, the company has always adhered to the principle of "global vision, serving health", continuously deepened its involvement in the field of cell technology, and carried out in-depth cooperation with many domestic top-tier medical institutions such as the 301 Hospital and Peking Union Medical College Hospital. It has completed more than 4,000 clinical cases and formed an ecological closed loop centered on "technology R&D - clinical transformation - data collection and upgrading - health service management".

In the future, CansBio will continue to uphold a scientific and rigorous R&D attitude, deeply integrate cell and gene technologies with precision medicine, and explore the positive significance of cell and gene technologies for human health.

Milestones

2007

Launched Sino-Japanese technological collaboration

2007: Launched Sino-Japanese technological collaboration, and simultaneously carried out NK cell immunotherapy in cooperation with the Chinese PLA General Hospital, initiating the localized exploration of tumor immunotherapy.

2007

2011

Strategically upgraded to Cansbio Biotechnology

2011: Strategically upgraded to Cansbio Biotechnology; in the following year, jointly established an immune cell research center with the Rocket Force General Hospital to tackle the problem of solid tumor treatment.

2011

2013-2014

Formed a dual-patent barrier

✅Applied for "Protein-cell Conjugate, Its Preparation Method and Use", and obtained authorization in China, the US and Japan in 2018.
✅Applied for a patent for "A Medium and Culture Method for Efficient Expansion of Autologous NK Cells", featuring stable process, high expansion multiple and high cell activity.

2013-2014

2015-2016

Develop novel therapeutic vaccines for liver cancer

Jointly developed a new type of therapeutic vaccine for liver cancer with the University of Florida.

2015-2016

2022

Clinical Research

Cooperated with Beijing Tongren Hospital to carry out clinical research on cell therapeutic vaccines.

2022

2023

Laid out a global R&D network

✅Reached cell technology cooperation intentions with the University of British Columbia (UBC) and Yale University (YALE).
✅Jointly completed the iterative upgrade of NK-PLUS medium with the National Institutes of Health (NIH, US).

2023

2024

Achieved three major milestones

✅ Launched the anti-aging blockbuster product "Runyan Miyu".
✅Obtained the five-star certification from CCX for "Autologous Immune Cell Storage Service".
✅ Cooperated with the team of Capital Medical University to carry out the project of "Mesenchymal Stem Cell-derived Exosomes for the Treatment of Acute Ischemic Stroke".